heblaj01
08-30-2006, 08:59 AM
For those who may want to attend the 2 day conference in Boston:
http://www.ibclifesciences.com/antiangio
October 16-17, 2006 - Sheraton Boston Hotel - Boston, MA
Part of the agenda is including:
Explore new targets for antiangiogenic therapy and receive clinical updates of agents now in development
Amgen, GlaxoSmithKline, Pfizer and Bayer share their latest clinical results and updates
Genentech describes their research on neuropilin-1, a new potential angiogenesis target
ARIAD Pharmaceuticals offers an in-depth look at mTOR inhibition for dual targeting of tumor prolifieration and angiogenesis
Dana Farber Cancer Center provides new data showing metronomic chemotherapy as anti-angiogenic treatment
http://www.ibclifesciences.com/antiangio
October 16-17, 2006 - Sheraton Boston Hotel - Boston, MA
Part of the agenda is including:
Explore new targets for antiangiogenic therapy and receive clinical updates of agents now in development
Amgen, GlaxoSmithKline, Pfizer and Bayer share their latest clinical results and updates
Genentech describes their research on neuropilin-1, a new potential angiogenesis target
ARIAD Pharmaceuticals offers an in-depth look at mTOR inhibition for dual targeting of tumor prolifieration and angiogenesis
Dana Farber Cancer Center provides new data showing metronomic chemotherapy as anti-angiogenic treatment